Qure AI

Qure AI leverages advanced AI to enhance healthcare diagnostics, focusing on  radiology with ai . Its tools, like qXR, rapidly analyze chest X-rays to detect conditions like lung cancer and tuberculosis, improving early diagnosis and treatment. Qure AI's solutions reduce turnaround time by 40%, ensuring faster patient care and efficient workflow for medical professionals. With deployment across 2600+ sites in over 90 countries, Qure AI demonstrates significant global impact, aiding in accurate, timely medical decisions and better patient outcomes. This platform in  Healthcare  is designed for seamless integration and scalability in diverse healthcare settings.

• Early Detection of Tuberculosis: Qure AI’s qXR tool swiftly analyzes chest X-rays to identify TB, reducing the time from screening to diagnosis from weeks to less than a day, as seen in the Philippines.
• Lung Nodule Detection: qXR-LN enhances lung cancer detection by identifying nodules on chest X-rays, improving accuracy and aiding in early intervention, crucial in combating lung cancer’s high mortality rate​​.
• Emergency Care: qER assists in rapid detection of multiple types of intracranial hemorrhages, cranial fractures, and other critical findings in head CT scans, significantly reducing diagnosis time in emergency settings​.
• Radiology Workflow Integration: Qure AI seamlessly integrates with existing radiology workflows, enhancing efficiency and reducing burnout among radiologists by automating routine tasks and prioritizing critical cases​.

Qure AI offers its advanced healthcare diagnostic tools for free. This makes it accessible to a wide range of medical facilities, ensuring that more patients can benefit from accurate and timely diagnoses without the burden of additional costs. This initiative supports global health improvement by providing essential diagnostic capabilities at no expense.

Qure AI was founded by Prashant Warier, who also serves as the CEO. The team is dedicated to advancing healthcare diagnostics using innovative technology. They have built a range of tools to improve the accuracy and speed of medical image analysis, focusing on conditions like tuberculosis and lung cancer. Their efforts have led to global deployment, impacting patient care in over 90 countries. The team's expertise and commitment drive Qure AI's mission to make healthcare more accessible and efficient worldwide.



Prashant Warier

CEO & Founder

Qure Ai has secured $60.3 million in total funding. Their latest round, Series D, announced on June 25, 2024, was led by Merck Global Health Innovation Fund. Previously, they raised $40 million in a Series C round on March 30, 2022, with investments from HealthQuad and Novo Holdings. Additionally, they received a £3.2 million grant from SBRI Healthcare on February 7, 2022, and $16 million from Peak XV Partners during a venture round on February 26, 2020. This funding supports Qure AI's mission to enhance healthcare diagnostics globally.